|
2.6 Etiologie - Environnement
|
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
|
3.8 Prévention - Alimentation
|
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
4.7 Dép., diag. & prono. - Col de l'utérus
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
Scotland’s TCB inks CAR-T deal with Japan’s NIPRO [PharmaTimes]
|
|
|
|
|
|
The
group has signed a strategic collaboration with Osaka, Japan-based The
NIPRO Corp to co-develop a novel immunotherapy product using TCB’s safe
CAR-T platform, ImmuniCAR, which utilises unique properties of modified
gamma-delta T cells to selectively target cancer whilst leaving healthy
cells untouched.
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
At Verastem, Infinity’s Former Blood Cancer Drug Heads to FDA [Xconomy]
|
|
|
|
|
|
If
approved, duvelisib, a pill that blocks PI3 kinases, a well known
cancer target, would be Verastem’s first marketed product—a twist of
fate considering Verastem started out developing stem cell therapies for
cancer and duvelisib has been in the hands of several other drugmakers
over the years.
|
|
|
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
5.5.14 ASCO (vessie)
|
|
|
|
5.5.3 ASCO (prostate)
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
The Future of Precision Medicine in Australia [ACOLA]
|
|
|
|
|
|
ACOLA’s
precision medicine project explores the current trends in precision
medicine technologies and explores the role that a broader
implementation of precision medicine capabilities may play in the
Australian context.
|
|
|
|
|
|
|
Last Month in Oncology with Dr. Bishal Gyawali: January 2018 [ecancernews]
|
|
|
|
|
|
We
have known for some time now that RECIST is not a good metric to
evaluate response with immunotherapies in cancer. This new study shows
that some patients may benefit with continuation of immunotherapies
beyond progression, but a better conclusion would be that RECIST is not a
good metric for immunotherapy.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.6 Publications
|
|
|